- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 92,080 | 08.07.24 17:35:55 | +0,780 | +0,85% | 0,000 | 0,000 | 91,270 | 91,300 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.052,740 | 08.07.24 20:21:45 | +18,510 | +1,79% | 1.051,700 | 1.053,020 | 1.039,510 | 1.034,230 |
